星昊医药
(430017)
| 流通市值：9.31亿 | | | 总市值：14.51亿 |
| 流通股本：7864.49万 | | | 总股本：1.23亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 154,300,499.21 | 721,995,870.96 | 519,796,894.08 | 331,059,461.91 |
| 营业收入 | 154,300,499.21 | 721,995,870.96 | 519,796,894.08 | 331,059,461.91 |
| 已赚保费 | - | 0 | 0 | - |
| 手续费及佣金收入 | - | 0 | 0 | - |
| 二、营业总成本 | 135,989,341.13 | 657,118,679.52 | 474,829,103.92 | 289,310,653.2 |
| 营业成本 | 40,638,493.25 | 186,793,336.05 | 125,295,882.7 | 80,370,845.39 |
| 利息支出 | - | 0 | 0 | - |
| 手续费及佣金支出 | - | 0 | 0 | - |
| 退保金 | - | 0 | 0 | - |
| 赔付支出净额 | - | 0 | 0 | - |
| 提取保险合同准备金净额 | - | 0 | 0 | - |
| 保单红利支出 | - | 0 | 0 | - |
| 分保费用 | - | 0 | 0 | - |
| 税金及附加 | 1,318,632.98 | 10,624,563.27 | 4,881,380.97 | 3,598,676.73 |
| 销售费用 | 65,388,168.62 | 325,539,875.73 | 242,274,769.32 | 152,953,609.9 |
| 管理费用 | 12,837,828.63 | 65,618,572.75 | 34,921,089.34 | 19,780,708.11 |
| 研发费用 | 17,909,848.02 | 73,184,198.6 | 70,264,892.66 | 33,391,197.52 |
| 财务费用 | -2,103,630.37 | -4,641,866.88 | -2,808,911.07 | -784,384.45 |
| 其中:利息费用 | 59,402.78 | 127,292.67 | 60,708.33 | 652.78 |
| 其中:利息收入 | 2,188,310.89 | 4,843,023.06 | 2,891,622.17 | 799,211.03 |
| 加:公允价值变动收益 | 2,426,856.18 | 2,296,560.29 | 3,864,138.63 | 2,678,022.47 |
| 加:投资收益 | 303,459.89 | 9,175,626.9 | 4,329,921.3 | 2,391,994.28 |
| 净敞口套期收益 | - | 0 | 0 | - |
| 汇兑收益 | - | 0 | 0 | - |
| 资产处置收益 | 0 | 132,519.41 | 122,919.47 | -10,021.75 |
| 资产减值损失(新) | 103,724.2 | -1,286,909.96 | -972,204.04 | -613,575.02 |
| 信用减值损失(新) | -295,661.57 | -1,424,332.1 | -453,484.47 | -11,067.47 |
| 其他收益 | 4,749,697.03 | 32,605,729.55 | 26,185,043.01 | 9,088,047.84 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 25,599,233.81 | 106,376,385.53 | 78,044,124.06 | 55,272,209.06 |
| 加:营业外收入 | 1,499.99 | 412,889.51 | 324,913.99 | 153,386.8 |
| 减:营业外支出 | 23,160.9 | 3,890,160.86 | 301,680.5 | 10,422.18 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 25,577,572.9 | 102,899,114.18 | 78,067,357.55 | 55,415,173.68 |
| 减:所得税费用 | 1,375,003.02 | 12,847,861.41 | 5,154,457.78 | 1,860,370.88 |
| 六、净利润 | 24,202,569.88 | 90,051,252.77 | 72,912,899.77 | 53,554,802.8 |
| 其中:被合并方在合并前实现利润 | - | 0 | 0 | - |
| 持续经营净利润 | 24,202,569.88 | 90,051,252.77 | 72,912,899.77 | 53,554,802.8 |
| 终止经营净利润 | - | 0 | 0 | - |
| 归属于母公司股东的净利润 | 24,952,836.79 | 92,723,545.76 | 72,787,269.73 | 53,402,300.97 |
| 少数股东损益 | -750,266.91 | -2,672,292.99 | 125,630.04 | 152,501.83 |
| (一)基本每股收益 | 0.2 | 0.84 | 0.69 | 0.55 |
| (二)稀释每股收益 | 0.2 | 0.84 | 0.69 | 0.55 |
| 八、其他综合收益 | 226.41 | -476,778.19 | -5,013.37 | 5,447.2 |
| 归属于母公司股东的其他综合收益 | 226.41 | -476,778.19 | -5,013.37 | 5,447.2 |
| 九、综合收益总额 | 24,202,796.29 | 89,574,474.58 | 72,907,886.4 | 53,560,250 |
| 归属于母公司股东的综合收益总额 | 24,953,063.2 | 92,246,767.57 | 72,782,256.36 | 53,407,748.17 |
| 归属于少数股东的综合收益总额 | -750,266.91 | -2,672,292.99 | 125,630.04 | 152,501.83 |
| 公告日期 | 2024-04-26 | 2024-04-22 | 2023-10-20 | 2023-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |